We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.026 | -1.79% | 1.425 | 1.402 | 1.448 | 1.42 | 1.41 | 1.42 | 3,614,132 | 16:35:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -6.69M | -0.0059 | -2.39 | 16.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
27/2/2018 10:24 | Chart courtesy of rosolanor https://twitter.com/ | leonsito | |
27/2/2018 09:59 | L2 looking like a few more sells will push this further down. | jimmyhoffa262 | |
27/2/2018 09:45 | ToptrumpWtfru people dont have to ask u before they buy or sell this is a great company theres nothing wrong with trading the waves i bought at 4 sold at 6 doesnt mean im not confident here nothing goes up in straight line i bought after reading hazl post | mally6 | |
27/2/2018 09:38 | As I say I try to be honest. I am amazed you have the audacity to post here after your embarrassing show yesterday. You knew absolutely nothing about the company and nothing about me, yet were willing to spout on about both. Here you are again! This company was already up when I joined the throng. It clearly had a break-through and the RNS proved it,completely contrary to your little researched comments! Look to yourself before you criticise others! | hazl | |
27/2/2018 09:32 | Post 240 hazl26 Feb '18 - 20:48 - 240 of 266 0 1 0 "Only fair to say....having said that I intended to keep them long term.... that I am not keen on the whole chimera thing. Humanised mice seems wrong to me. So I won't be posting but I expect the share to continue to do well." Yeah, right. More like you sold out as I said you would after ramping it all day or even more likely sold after it fell and before the rns without a profit. Such is the whole bulletin board purpose for you short term trading guys (or gambling losers) Not sure what to make of the rns, I wouldn't invest on principal and even if it were ethical the time to market and huge cash burn that these early stage bios go through prevents any profit for years and years, if at all. Roulette stock. | toptrump1 | |
27/2/2018 09:29 | volume has dried up so I think you may have your way on recovery today..watching | tsmith2 | |
27/2/2018 09:29 | IMHO a MCAP of £50-60M for a company like HEMO, at this stage, is quite reasonable. Under current shares issued that would give an share price of 15-17p but no doubt you can probably expect rights issues etc before then...... as always DYOR and GLTA | citycanary | |
27/2/2018 09:16 | This will bounce off 5p today.Themms want your stock.The directors are well invested here. I will be disappointed not to see 7p this week RAMP OVER!!! | billthebank | |
27/2/2018 09:15 | How.much good news can you squeeze into one RBS!!!!! | billthebank | |
27/2/2018 09:14 | Vladislav Sandler, CEO & Co-Founder of Hemogenyx, commented: "We are hugely excited by the first solid data that we've received testing the efficacy of CDX antibodies against Acute Myelogenous Leukemia. The results which show that they can attack and eliminate AML cells is a true breakthrough and a significant development in our process of developing CDX to become a universally available conditioning product for patients undergoing bone marrow transplants as a treatment for serious blood diseases. "In addition the new type of humanised mice opens the door to extending our work into other disease models and specific drug development which we expect to be of great interest to large biopharmaceutical companies and could form the basis of a number of significant future collaborations." | billthebank | |
27/2/2018 09:12 | First data results have shown that CDX bi-specific antibodies are capable of attacking and eliminating the blood cancer Acute Myelogenous Leukemia (AML) in vitro. | billthebank | |
27/2/2018 09:11 | The Company can confirm that it has filed a provisional patent application relating to the Company's development of a new type of humanised mice with a chimeric mouse-human blood system that can be used to advance product development, as well as for other disease modelling and drug development. | billthebank | |
27/2/2018 09:10 | Lead candidate shown to be effective in treatment of Leukemia | billthebank | |
27/2/2018 09:09 | This will be pushing 7p this week | billthebank | |
27/2/2018 09:09 | Shake.... well done those in profit unlucky to those that are now trapped! Check out BOIL great news just landed, can move very quickly. | oildon11 | |
27/2/2018 09:09 | A big shake.Re read the RNS | billthebank | |
27/2/2018 09:04 | A little shake? | tsmith2 | |
27/2/2018 08:14 | Well it's up 200% already, so a good trade, good luck if your left in. I wnt risk more at this price. | jimmyhoffa262 | |
27/2/2018 08:12 | Shook out the weak traders. .watch this motor now | momentum1 | |
27/2/2018 08:05 | I'm out, just in case profit is profit | jimmyhoffa262 | |
27/2/2018 07:36 | Pleased for you moormoney........you find us the next ! | hazl | |
27/2/2018 06:42 | 8p? Think bigger.... | babbler | |
27/2/2018 05:00 | Then again, most think that this share is listed on our AIM. Which it is not. | lufc5 | |
27/2/2018 04:58 | There has been talk of this potentially getting suspended first thing, due to "the tweet". My take is, would it not have been on the stoke of the rns, or moments before? | lufc5 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions